Explore how daratumumab treatment triggers microvesicle release in multiple myeloma cells and the implications for cancer therapy resistance.
Explore how JAM-A protein drives multiple myeloma progression through cellular adhesion, angiogenesis, and its potential as therapeutic target and prognostic biomarker.